Personalized cancer vaccine for solid tumors with residual disease
Treatments studied
Part of Cancer, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a personalized cancer vaccine designed to help your immune system fight any remaining cancer cells after surgery. It is for people with certain solid tumors—like bladder, stomach, melanoma, or lung cancer—that show signs of disease through a blood test.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have had surgery to remove all visible cancer, and a blood test shows cancer cells may still be present.
- You have one of these cancers: bladder, upper urinary tract, stomach, melanoma, or non-small cell lung cancer.
- You are in good general health, able to do daily activities, and have adequate organ function.
- You have not had severe allergic reactions to vaccines or have an active autoimmune disease.
- You agree to use birth control during the trial and for a period after treatment, if relevant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized cell therapy made from your own immune cells, changed to recognize “neoantigens” on cancer cells. It’s designed for people with metastatic (advanced spread) solid cancers or certain other cancers who have tried standard treatments but cancer is still growing.
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
This trial offers access to a personalized vaccine made from your tumor's unique markers (neoantigens). The goal is to train your immune system to fight your cancer. You may qualify if standard treatments have not worked or are not an option, and your doctor believes your 5-year survival chance is under 50%.
This trial tests a personalized cancer vaccine made from synthetic long peptide “neoantigens,” aiming to be safe and help the immune system fight certain solid tumors. It may fit people with pancreatic cancer after starting first-line chemotherapy, and some other solid tumors with limited options.
This trial tests a personalized vaccine made from your cancer's unique markers. The goal is to train your immune system to fight the cancer, potentially slowing it down when other options have run out.
This trial tests a personalized vaccine (ODI-2001) that is made from your own tumor. It is given during a break from chemotherapy to see if it is safe and can help keep the cancer from growing.
Hear when a new Muscle-Invasive Bladder Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.